NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace
NeuroOne Medical Technologies (Nasdaq: NMTC) CEO Dave Rosa appeared on Today's Marketplace to discuss epilepsy treatment innovations alongside Dr. Jessica Clark from Creighton University. The discussion centered on the company's OneRF® Ablation System, which is the first and only FDA 510(k)-cleared device that can both record brain activity and perform RF ablation using the same device.
The system consists of three main components: an electrode for stimulation, recording, and monitoring brain activity with ablation capability, a temperature probe, and a radio frequency heat generator system. This innovation addresses a critical need, as over 50 million people worldwide suffer from epilepsy, with approximately one-third of patients experiencing medication-resistant seizures.
NeuroOne Medical Technologies (Nasdaq: NMTC) Il CEO Dave Rosa è apparso su Today's Marketplace per discutere delle innovazioni nel trattamento dell'epilessia insieme alla Dr.ssa Jessica Clark dell'Università di Creighton. La discussione si è concentrata sul OneRF® Ablation System dell'azienda, che è il primo e unico dispositivo approvato dalla FDA 510(k) in grado di registrare l'attività cerebrale e di eseguire ablazione RF utilizzando lo stesso dispositivo.
Il sistema è composto da tre componenti principali: un elettrodo per stimolazione, registrazione e monitoraggio dell'attività cerebrale con capacità di ablazione, una sonda di temperatura e un sistema generatore di calore a radiofrequenza. Questa innovazione risponde a un bisogno critico, poiché oltre 50 milioni di persone in tutto il mondo soffrono di epilessia, con circa un terzo dei pazienti che sperimenta crisi resistenti ai farmaci.
NeuroOne Medical Technologies (Nasdaq: NMTC) El CEO Dave Rosa apareció en Today's Marketplace para discutir innovaciones en el tratamiento de la epilepsia junto a la Dra. Jessica Clark de la Universidad de Creighton. La discusión se centró en el OneRF® Ablation System de la compañía, que es el primer y único dispositivo aprobado por la FDA 510(k) que puede grabar la actividad cerebral y realizar ablación por RF utilizando el mismo dispositivo.
El sistema consta de tres componentes principales: un electrodo para estimulación, grabación y monitoreo de la actividad cerebral con capacidad de ablación, una sonda de temperatura y un sistema generador de calor por radiofrecuencia. Esta innovación aborda una necesidad crítica, ya que más de 50 millones de personas en todo el mundo sufren de epilepsia, con aproximadamente un tercio de los pacientes experimentando convulsiones resistentes a los medicamentos.
NeuroOne Medical Technologies (Nasdaq: NMTC) CEO 데이브 로사는 Today's Marketplace에 출연하여 Creighton University의 제시카 클락 박사와 함께 간질 치료 혁신에 대해 논의했습니다. 논의는 회사의 OneRF® Ablation System에 초점을 맞추었으며, 이는 뇌 활동을 기록하고 동일한 장치를 사용하여 RF 절제를 수행할 수 있는 최초이자 유일한 FDA 510(k) 승인 장치입니다.
이 시스템은 세 가지 주요 구성 요소로 구성되어 있습니다: 자극, 기록 및 모니터링을 위한 전극과 절제 기능, 온도 프로브 및 고주파 열 생성기 시스템. 이 혁신은 전 세계적으로 5천만 명 이상이 간질로 고통받고 있으며, 약 3분의 1의 환자가 약물 저항성 발작을 경험한다는 중요한 필요를 해결합니다.
NeuroOne Medical Technologies (Nasdaq: NMTC) Le PDG Dave Rosa est apparu sur Today's Marketplace pour discuter des innovations dans le traitement de l'épilepsie aux côtés de Dr. Jessica Clark de l'Université de Creighton. La discussion était centrée sur le OneRF® Ablation System de l'entreprise, qui est le premier et unique dispositif approuvé par la FDA 510(k) capable d'enregistrer l'activité cérébrale et d'effectuer une ablation RF avec le même dispositif.
Le système se compose de trois composants principaux : un électrode pour la stimulation, l'enregistrement et la surveillance de l'activité cérébrale avec capacité d'ablation, une sonde de température, et un système de générateur de chaleur à radiofréquence. Cette innovation répond à un besoin critique, car plus de 50 millions de personnes dans le monde souffrent d'épilepsie, avec environ un tiers des patients éprouvant des crises résistantes aux médicaments.
NeuroOne Medical Technologies (Nasdaq: NMTC) CEO Dave Rosa trat auf Today's Marketplace auf, um über Innovationen in der Epilepsiebehandlung zusammen mit Dr. Jessica Clark von der Creighton University zu sprechen. Die Diskussion konzentrierte sich auf das OneRF® Ablation System des Unternehmens, das das erste und einzige von der FDA 510(k) zugelassene Gerät ist, das sowohl die Gehirnaktivität aufzeichnen als auch RF-Ablation mit demselben Gerät durchführen kann.
Das System besteht aus drei Hauptkomponenten: einer Elektrode zur Stimulation, Aufzeichnung und Überwachung der Gehirnaktivität mit Ablationsfähigkeit, einer Temperatursonde und einem Hochfrequenzwärmeerzeugungssystem. Diese Innovation spricht ein kritisches Bedürfnis an, da weltweit über 50 Millionen Menschen an Epilepsie leiden, wobei etwa ein Drittel der Patienten medikamentenresistente Anfälle hat.
- First and only FDA 510(k)-cleared device combining brain activity recording and RF ablation
- Addresses large market of 50 million epilepsy patients worldwide
- Potential expansion into pain management applications
- Reduces need for multiple invasive surgeries
- None.
EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today’s Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne’s breakthrough OneRF® Ablation System.
The full interview can be viewed online here.
Over 50 million people worldwide are affected by epilepsy, with nearly one-third of patients experiencing seizures that do not respond to medication. For these individuals, alternative treatment options, including Radiofrequency (RF) ablation therapy, offer a promising solution.
NeuroOne’s OneRF® ablation system, is the first and only FDA 510(k)-cleared device capable of both recording brain activity and performing an RF ablation using the same device. The system has three main components: an electrode that stimulates, records and monitors brain activity with the capability to also perform an ablation, a temperature probe, and a radio frequency heat generator system.
"It was my pleasure to take part in this engaging conversation with Elizabeth Hart and Dr. Clark about the latest treatment options for epilepsy. The OneRF® system represents a significant advancement, offering a more efficient and precise approach for patients who still experience seizure activity after using traditional medication options," said Dave Rosa, CEO of NeuroOne. "By combining real-time monitoring with targeted ablation in a single procedure, we are not only improving patient outcomes but also reducing the need for multiple invasive surgeries."
To learn more about NeuroOne and its groundbreaking work in epilepsy treatment, as well as the potential for our OneRF® platform to be used in pain management, please visit nmtc1.com.
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential for our OneRF® platform to be used in pain management our business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
Caution: Federal law restricts this device to sale by or on the order of a physician.
IR Contact
Chris Donovan
MZ Group – MZ North America
(914) 352-5853
NMTC@mzgroup.us
FAQ
What makes NeuroOne's OneRF® Ablation System unique for epilepsy treatment?
How many components does NMTC's OneRF® system include?
What market size is NMTC's OneRF® system targeting in epilepsy treatment?
What additional applications is NMTC exploring for the OneRF® platform?
